The majority of Hh modulators developed so far act as antagonists of the upstream Smo receptor, and two Smo antagonists (Vismodegib and Sonidegib) have been approved by the FDA for the treatment of advanced or metastatic BCC. Here, SMO is linked to skin basal cell carcinoma.